Mab

Suicidal Angel

by Mab
Astrophel

by Mab
Mab

by Elvira Madigan
More

by Mab
Candyman

by Mab
Black

by Mab
Scared Of The Darkness

by Mab
Decay

by Mab
Pure

by Mab
Pearl

by Mab

Suicidal Angel

by: Mab

I saw you for the last time
It was raining just like know
You smiled at me... if I only had know
I'm walking behind you with people that once was your
life...
Suicidal angel your choice was to die
And leave me alone in this empty and sad world
But babe this sorrow won't change what is wrong!
What was your pain? What was your pain?
Wasn't love enough? If you only had know...
My chance to tell you it's well gone right now!
It's gone! It's all lost!
Suicidal angel your choice was to die
And leave me alone in this empty and sad world
But babe this sorrow won't change what is wrong!
Why! Why!
You had to fly... you had to fly...
Why! It's a lie!
Tell me you will rise tonight!
Tell me you will rise!!
Ah... la vita che stanca... ma è vita!

Latest News for: mab

Edit

Refractory Metastatic Melanoma Pipeline Report 2025, with Focus on BioNTech SE, Y-mAbs and Therapeutics Seagen

Nasdaq Globe Newswire 20 Mar 2025

Dublin, March 20, 2025 (GLOBE NEWSWIRE) -- The "Refractory Metastatic Melanoma - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering ... It further highlights the inactive pipeline products in this space.

Edit

Henlius Receives Orphan Drug Designation for Innovative Anti-HER2 mAb HLX22 in the U.S. for Gastric Cancer

PR Newswire 19 Mar 2025

(2696.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for HLX22, the company's innovative anti-HER2 monoclonal antibody (mAb) for the treatment of gastric cancer. .

Edit

Statement of Changes in Beneficial Ownership (Form 4) (Y-mAbs Therapeutics Inc)

Public Technologies 12 Mar 2025

) FORM 4. Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue ... 0.5 ... 2 ... Y-mAbs Therapeutics, Inc ... C/O Y-MABS THERAPEUTICS, INC., 202 CARNEGIE CENTER, SUITE 301 3 ... C/O Y-MABS THERAPEUTICS, INC ... Y-mAbs Therapeutics Inc.

Edit

I-Mab Announces Accelerated Givastomig Phase 1b Study Progress

Nasdaq Globe Newswire 07 Mar 2025

ROCKVILLE, Md., March 07, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ ... The Phase 1b program includes a dose escalation study (n=17) and a dose expansion study (n=40) ... .

Edit

I-Mab Announces Accelerated Givastomig Phase 1b Study Progress (Form 6-K) (I-Mab)

Public Technologies 07 Mar 2025

I-Mab Announces Accelerated Givastomig Phase 1b Study Progress • Enrollment completed ahead of schedule in the first dose expansion cohort ... ROCKVILLE, MD, March 7, 2025 (GLOBE NEWSWIRE) - I-Mab (NASDAQ ... About I-Mab. I-Mab (NASDAQ.

Edit

Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments

Nasdaq Globe Newswire 04 Mar 2025

Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments ... .

Edit

2025 Anti-CD38 Antibody Pipeline Insights for 10+ Companies and 12+ Pipeline Drugs, Including Felzartamab (I-MAB ...

Nasdaq Globe Newswire 04 Mar 2025

Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "Anti-CD38 Antibody - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering ... It covers the pipeline drug profiles, including clinical and nonclinical stage products.

Edit